Monday, 26 December 2022

Alembic Pharma receives USFDA final approval for Fulvestrant Injection

Alembic Pharma receives USFDA final approval for Fulvestrant Injection Pradip Mahajan Mon, 12/26/2022 - 15:13

Alembic Pharmaceuticals Limited (Alembic) announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per Single- Dose Prefilled Syringe.



source https://www.pharmatutor.org/pharma-news/2022/alembic-pharma-receives-usfda-final-approval-for-fulvestrant-injection
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Career for Pharmacy and Biotech at National Agri-Food and Biomanufacturing Institute

Positions: Junior Research Fellow (JRF) (One) Master’s Degree from a recognized University/Institute in M.Sc. Chemistry - Organic / Physical...